Logo
Whalesbook
HomeStocksNewsPremiumAbout UsContact Us

Lupin Ltd

₹ 2,0920.57%
04 Dec – close price
🔗lupin.com•BSE: 500257•NSE: LUPIN
Market Cap₹ 95,532 Cr.
Current Price₹ 2,092
High / Low₹ 2,403
Stock P/E17.9
Book Value₹ 596
Dividend Yield0.57 %
ROCE21.9 %
ROE17.8 %
Face Value₹ 2.00
Sales₹ 18,471 Cr.
OPM38.2 %
Mar Cap₹ 95,532 Cr.

ABOUT

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

KEY POINTS

ProductsCo. is engaged in developing and marketing generic formulations, biotechnology products, and APIs globally. Co. has a significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, and Central Nervous system, among other segments, and is a global leader in e Anti-TB and Cephalosporins segments.[1]

Also present in buckets:
Aggressive Growth TriggersCapacity Expansion And ProductsLarge Order ReceiptsJv Partnerships Acquisitions

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1818.3037.81436512.690.883124.952.5614478.318.9320.2154964.0130.1211543.963117.955.6112.970.07
2.Divi's Lab.6469.0069.11171747.590.46689.0035.102715.0016.1220.4410029.0032.372485.00689.0011.1413.530.01
3.Torrent Pharma.3795.7059.34128559.890.84591.0032.493302.0014.3027.0512248.0032.602166.53600.1715.2013.260.33
4.Cipla1521.0022.58122853.860.851353.373.737589.447.6422.7228349.5725.405441.141351.173.7314.720.01
5.Dr Reddy's Labs1277.6018.48106643.700.631336.807.288828.309.8322.6934310.0024.645772.201347.102.9612.950.16
6.Lupin2092.0017.9195531.680.571357.357.554068.28-0.9221.9118470.5438.245335.31868.743.5114.990.04
7.Zydus Lifesci.935.7518.7094062.771.181238.6040.926123.2016.9224.3124493.9031.105029.351283.603.7214.640.38
–Median: 148 Co.409.7731.791710.390.1212.5711.71152.6410.5314.85582.8715.9344.5513.493.188.390.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
2,8292,8612,8363,4963,6594,1163,3964,1684,1064,2084,4865,7094,068
Expenses
2,5152,6462,5742,7912,8242,8982,6962,9682,9912,7972,7402,9792,893
Operating Profit
3142152627058351,2177001,2001,1151,4111,7462,7301,176
Other Income
151755282623313833-224954663
Profit before tax
173671425776961,0844281,0839841,2171,5532,5881,636
Tax %
14%40%16%17%21%15%10%18%18%19%17%18%17%
Net Profit
149401194775499163848898089851,2912,1281,357
EPS in Rs
3.270.892.6210.4812.0520.138.4319.5017.7121.5828.2846.6029.72

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
8,9399,75211,34412,62610,08111,35611,02611,05611,77211,25914,66616,96818,471
Expenses
6,0166,3757,3578,1347,9928,5049,1169,01211,56010,29511,21611,57411,408
Operating Profit
2,9223,3773,9874,4922,0892,8531,9092,0442119643,4515,3947,062
Other Income
40517718782128-49-286129215210115176744
Interest
21524293335534173985684100
Depreciation
168337306366390426519503514548725648712
Profit before tax
3,1393,2123,8444,1791,7942,3421,0521,630-1625272,7854,8376,994
Net Profit
2,3242,3972,8313,1411,3451,5397281,259-1894252,3263,9735,761
EPS in Rs
51.8453.3462.8369.5629.7434.0116.0627.74-4.159.3551.0587.02126.18
Dividend Payout %
12%14%12%11%17%15%37%23%-96%43%16%14%–

Compounded Sales Growth

10 Years:6%
5 Years:9%
3 Years:13%
TTM:17%

Compounded Profit Growth

10 Years:5%
5 Years:28%
3 Years:173%
TTM:78%

Stock Price CAGR

10 Years:1%
5 Years:18%
3 Years:40%
1 Year:0%

Return on Equity

10 Years:11%
5 Years:8%
3 Years:11%
Last Year:18%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
90909090909091919191919191
Reserves
6,8898,93811,82314,69015,69517,02717,38318,47518,05918,32120,51224,18727,133
Borrowings
1444539259317664859517491052501,014
Other Liabilities
1,6751,9351,9312,4752,8792,5673,2012,8083,2123,5234,2153,9044,423
Total Liabilities
8,79911,00814,23617,84818,68119,69020,68021,85922,31322,68424,92328,43232,661
Fixed Assets
2,1792,0362,3453,0133,3413,3733,5143,6393,6904,0224,1134,9464,943
Gross Block
3,0893,3102,6493,6694,3734,8085,6666,2306,7057,4087,6058,673–
Accumulated Depreciation
9101,2753046561,0321,4352,1522,5913,0153,3863,4923,727–
CWIP
2674906244811,1711,199822951947927446278322
Investments
1,1643,4443,7416,9145,3637,3887,4569,5639,5119,97411,58111,95514,098
Other Assets
5,1895,0387,5267,4418,8067,7308,8887,7068,1657,7618,78311,25313,299
Total Assets
8,79911,00814,23617,84818,68119,69020,68021,85922,31322,68424,92328,43232,661

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
1,5282,8529174,3522093,1112,2191,5701511,7942,5042,445
Cash from Investing Activity
-447-1,178-2,629-1,941725-2,865-740-2,508-372-1,269-1,599-1,766
Cash from Financing Activity
-844-22117-160-987-295-368-53102-498-867-460
Net Cash Flow
2371,452-1,6962,252-52-501,112-991-1182738218

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
11794146113179120120105848796122
Inventory Days
174211214232229216216236260230216239
Days Payable
124126126161150118136104110119148146
Cash Conversion Cycle
166179234184258218199237234197163215
Working Capital Days
133115169127219171154146124110116153
ROCE %
50%40%36%30%11%16%10%9%-1%3%14%22%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
47.10%47.08%47.07%47.06%47.04%47.01%46.99%46.96%46.94%46.91%46.90%46.89%
FIIs
13.98%13.32%13.93%14.99%16.11%18.29%19.32%21.50%22.04%21.46%21.25%20.50%
DIIs
29.39%28.92%29.08%29.14%29.72%27.76%26.77%25.10%24.73%25.41%25.55%26.56%
Public
9.51%10.39%9.62%8.52%7.10%6.93%6.92%6.44%6.27%6.21%6.28%6.06%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Lupin Enters Licensing Agreement with Valorum for Biosimilar Armlupeg in U.S. (BSE)

4th December 2025, 1:22 PM

Lupin Receives US FDA Approval for Biosimilar Pegfilgrastim (Armlupeg)

1st December 2025, 7:44 AM

CRISIL Affirms Lupin Foundation's VO 1A Rating for Social Responsibility (BSE)

28th November 2025, 11:42 AM

Lupin Limited: US FDA Issues 7 Observations Post Goa Facility Inspection; Company Commits to Response

21st November 2025, 10:47 PM

Lupin Announces Successful US FDA Inspection at Nagpur Unit-1 Facility with Zero Observations

15th November 2025, 4:53 PM

Published by Other Websites

External media mentions & references

Lupin inks exclusive licensing agreement with US firm for biosimilar of its cancer drug

4th December 2025, 9:56 AM

AMFI stock rejig countdown: IPO stars prepare to topple the titans

4th December 2025, 7:49 AM

Novo Nordisk gears up for December Ozempic launch in India, sources say

4th December 2025, 5:19 AM

Novo Nordisk to launch diabetes drug Ozempic in India in December

4th December 2025, 1:55 AM

Intraday stocks to buy today: BEL, PB Fintech, Hyundai Motor, GE Shipping, Lupin

2nd December 2025, 5:15 AM

News Articles

Editorial & research coverage

Lupin inks exclusive licensing agreement with US firm for biosimilar of its cancer drug
Lupin inks exclusive licensing agreement with US firm for biosimilar of its cancer drug

4th December 2025, 9:56 AM

AMFI stock rejig countdown: IPO stars prepare to topple the titans
AMFI stock rejig countdown: IPO stars prepare to topple the titans

4th December 2025, 7:49 AM

Novo Nordisk to launch diabetes drug Ozempic in India in December
Novo Nordisk to launch diabetes drug Ozempic in India in December

4th December 2025, 1:55 AM

Intraday stocks to buy today: BEL, PB Fintech, Hyundai Motor, GE Shipping, Lupin
Intraday stocks to buy today: BEL, PB Fintech, Hyundai Motor, GE Shipping, Lupin

2nd December 2025, 5:15 AM

Narrow rally keeps broader market weak, stay selective, says Chola Securities' Kant
Narrow rally keeps broader market weak, stay selective, says Chola Securities' Kant

1st December 2025, 5:50 AM

Documents

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release

6h - Lupin licenses Armlupeg (pegfilgrastim-unne) to Valorum for US commercialization; Lupin supplies, receives upfront fee and royalties.

Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)

1 Dec - Lupin's Armlupeg (pegfilgrastim) FDA-approved; USD 1,295m U.S. market; manufactured in Pune; Dec 1, 2025.

Announcement under Regulation 30 (LODR)-Press Release / Media Release

28 Nov - LHWRF awarded CRISIL VO 1A rating on Nov 28, 2025 for strong delivery and financial proficiency.

U.S. FDA Has Conducted An Inspection At Company''s Manufacturing Facility Located At Goa, India.

21 Nov - U.S. FDA inspected Goa plant Nov 10–21, 2025; Form-483 issued with seven observations.

Announcement under Regulation 30 (LODR)-Press Release / Media Release

15 Nov - U.S. FDA Pre-Approval Inspection at Nagpur Unit-1 (Nov 10-14, 2025) concluded with zero 483 observations.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Financial Year 2012

(from nse)

Credit Ratings

Rating update

9 Oct from icra

Rating update

30 Jun from icra

Rating update

25 Apr 2024 from icra

Rating update

23 Feb 2023 from icra

Rating update

10 Nov 2021 from icra

Rating update

24 Sep 2021 from icra

Concalls

Nov 2025

TranscriptPPT

Aug 2025

TranscriptPPT

May 2025

TranscriptPPT

Feb 2025

TranscriptPPT

Nov 2024

TranscriptPPT

Aug 2024

Transcript

Aug 2024

TranscriptPPT

May 2024

TranscriptPPT

Feb 2024

TranscriptPPT

Nov 2023

TranscriptPPT

Aug 2023

TranscriptPPT

May 2023

TranscriptPPT

Feb 2023

TranscriptPPT

Jan 2023

PPT

Nov 2022

TranscriptPPT

Aug 2022

TranscriptPPT

May 2022

TranscriptPPT

Feb 2022

TranscriptPPT

Jan 2022

PPT

Nov 2021

TranscriptPPT

Aug 2021

TranscriptPPT

May 2021

TranscriptPPT

Feb 2021

TranscriptPPT

Jan 2021

PPT

Nov 2020

TranscriptPPT

Aug 2020

Transcript

Jun 2020

TranscriptPPT

Feb 2020

TranscriptPPT

Jan 2020

PPT

Nov 2019

Transcript

Nov 2019

TranscriptPPT

Aug 2019

PPT

May 2019

PPT

Feb 2019

TranscriptPPT

Jan 2019

PPT

Nov 2018

TranscriptPPT

Aug 2018

TranscriptPPT

Jun 2018

PPT

May 2018

PPT

Feb 2018

PPT

Jan 2018

PPT

Nov 2017

TranscriptPPT

Sep 2017

PPT

Aug 2017

PPT

May 2017

PPT

Feb 2017

PPT

Jan 2017

PPT

Nov 2016

PPT

Jun 2016

Transcript